Lymphome, Leukämien und hämatologische Neoplasien
Ansprechpartnerin:
Dr. med. Mirjeta Berisha
Tel.: 0391-6713266
E-Mail:
Erkrankung/Zentrum |
Indikation |
Name der Studie |
Kurzbeschreibung |
| Akute Myeloische Leukämie (AML) und Myelodysplastisches Syndrom (MDS) | AML | AMLSG 30-18 |
Randomized phase III study of standard intensive chemotherapy versus intensive chemotherapy with CPX-351 in adult patients with newly diagnosed AML and intermediate - or adverse genetics |
| Akute Myeloische Leukämie (AML) und Myelodysplastisches Syndrom (MDS) | AML/MDS-EB2 | HOVON 156 AML/ AMLSG 28-18 |
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by oneyear maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy |
| Akute Myeloische Leukämie (AML) und Myelodysplastisches Syndrom (MDS) | AML/MDS-EB2 | HOVON 150 AML/ AMLSG 29-18 |
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy |
| Akute Myeloische Leukämie (AML) und Myelodysplastisches Syndrom (MDS) | AML/high-risk MDS | AMLSG Bio |
Registry study on patient characteristics, biological disease profile and clinical outcome in Acute Myeloid Leukemia and related neoplasms, and higher risk myelodysplastic syndrome the Biology and Outcome (BiO)-Project |
| Akute Myeloische Leukämie (AML) und Myelodysplastisches Syndrom (MDS) | AML | Enhance-3 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy |
| Akute Lymphatische Leukämie (ALL) | ED ALL | GMALL-Register |
GMALL-Register und Biomaterialbank Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen |
| Non-Hodgkin Lymphom (NHL) | r/r DLBL | POLA-R-ICE |
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL) |
| Non-Hodgkin Lymphom (NHL) | Vorerst Einschluss nur von Patienten mit FL möglich | MZoL-FL-Register |
Nicht-interventionelles, prospektives Register |
| Non-Hodgkin Lymphom (NHL) | T-NHL | T-NHL Register und Biomaterialbank |
Register und Biomaterialdatenbank für reifzellige systemische T-Zell Lymphome (T-NHL) der German Lymphoma Alliance (GLA) und der Ostdeutschen Studiengruppe Hämatologie und Onkologie (OSHO) |
| Lymphom des Zentralen Nervensystems (ZNS) | primäres ZNS-Lymphom | OptiMATe |
Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial |
| Chronische Lymphatische Leukämie (CLL) | ED high-risk CLL | CLL-16 |
A prospective, open-label, multicenter, randomized, phase 3 trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) compared to Obinutuzumab and Venetoclax (GVE) in previously untreated patients with high-risk (17p-deletion, tp53-mutation or complex karyotype) chronic lymphocytiv leukemia (CLL) |